Dimerix Ltd (ASX: DXB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Dimerix Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$126.08 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
600.40 million
Earnings per share
-0.050
Dividend per share
N/A
Year To Date Return
-60.00%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Dimerix Ltd (ASX: DXB)
Latest News
Healthcare Shares
Why is this ASX biotech rocketing more than 20%?
Share Gainers
Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher
Share Gainers
Why Dimerix, Evolution Mining, Inghams, and NextDC shares are charging higher today
Share Gainers
Why Boss Energy, Capstone, Dimerix, and Platinum shares are storming higher today
Healthcare Shares
Guess which ASX All Ords stock is rocketing 58% on big US news
Healthcare Shares
Guess which ASX healthcare stock is up 31% on big news
Share Gainers
Why Dimerix, Paladin Energy, Pilbara Minerals, and Resolute Mining shares are storming higher today
Share Fallers
Why Dimerix, Life360, S2 Resources, and SG Fleet shares are sinking today
ASX Share Market News
Top 10 most traded ASX shares and US stocks in June
Share Fallers
Why Dimerix, New Hope, Pro Medicus, and West African Resources shares are sinking today
Share Gainers
If you invested $5,000 in this ASX healthcare stock a year ago, you'd have $50,833 now!
Healthcare Shares
2 ASX biotech shares that could be the next Telix Pharmaceuticals
DXB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Dimerix Ltd
Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. It focuses on the development of Dimerix' DMX-200 drug candidate in both renal and respiratory indications and the development of Dimerix' DMX-700 pre-clinical asset in Chronic Obstructive Pulmonary Disease (COPD). The company was founded on May 13, 1975 and is headquartered in Melbourne, Australia.
DXB Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Oct 2026 | $0.22 | $0.00 | 0.00% | 272,987 | $0.22 | $0.22 | $0.22 |
| 12 Oct 2026 | $0.22 | $0.00 | 0.00% | 438,080 | $0.24 | $0.24 | $0.22 |
| 09 Oct 2026 | $0.22 | $0.00 | 0.00% | 325,000 | $0.23 | $0.23 | $0.22 |
| 08 Oct 2026 | $0.22 | $-0.01 | -4.44% | 438,756 | $0.23 | $0.23 | $0.22 |
| 07 Oct 2026 | $0.23 | $-0.01 | -4.35% | 638,201 | $0.23 | $0.23 | $0.22 |
| 06 Oct 2026 | $0.23 | $0.00 | 0.00% | 975,412 | $0.24 | $0.24 | $0.23 |
| 05 Oct 2026 | $0.24 | $0.01 | 4.44% | 830,659 | $0.23 | $0.25 | $0.23 |
| 02 Oct 2026 | $0.23 | $-0.01 | -4.26% | 402,282 | $0.23 | $0.23 | $0.23 |
| 01 Oct 2026 | $0.24 | $0.00 | 0.00% | 525,796 | $0.24 | $0.24 | $0.23 |
| 30 Sep 2026 | $0.23 | $0.00 | 0.00% | 271,613 | $0.24 | $0.24 | $0.23 |
| 29 Sep 2026 | $0.23 | $0.00 | 0.00% | 387,718 | $0.24 | $0.24 | $0.23 |
| 28 Sep 2026 | $0.24 | $0.01 | 4.44% | 686,422 | $0.24 | $0.24 | $0.23 |
| 25 Sep 2026 | $0.23 | $-0.01 | -4.26% | 605,478 | $0.24 | $0.24 | $0.23 |
| 24 Sep 2026 | $0.24 | $0.00 | 0.00% | 1,094,284 | $0.24 | $0.24 | $0.23 |
| 23 Sep 2026 | $0.24 | $-0.01 | -4.17% | 1,414,555 | $0.24 | $0.24 | $0.23 |
| 22 Sep 2026 | $0.24 | $0.01 | 4.26% | 305,261 | $0.24 | $0.24 | $0.24 |
| 21 Sep 2026 | $0.24 | $-0.01 | -4.08% | 927,640 | $0.26 | $0.26 | $0.24 |
| 18 Sep 2026 | $0.25 | $0.00 | 0.00% | 1,558,801 | $0.25 | $0.26 | $0.24 |
| 17 Sep 2026 | $0.25 | $0.01 | 4.17% | 286,203 | $0.24 | $0.25 | $0.24 |
| 16 Sep 2026 | $0.24 | $0.01 | 4.26% | 849,293 | $0.25 | $0.25 | $0.23 |
| 15 Sep 2026 | $0.24 | $-0.01 | -4.17% | 817,578 | $0.24 | $0.25 | $0.24 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 12 Dec 2025 | Mark Diamond | Issued | 300,000 | $96,300 |
Issue of options. $96,300 (Black-Scholes valuation)
|
| 12 Dec 2025 | Hugh Alsop | Issued | 300,000 | $96,300 |
Issue of options. $96,300 (Black-Scholes valuation)
|
| 12 Dec 2025 | Nina Webster | Issued | 2,500,000 | $1,093,500 |
Issue of options. $1,093,500 (Black-Scholes valuation)
|
| 12 Dec 2025 | Sonia Poli | Issued | 300,000 | $96,300 |
Issue of options. $96,300 (Black-Scholes valuation)
|
| 12 Dec 2025 | Clinton Snow | Issued | 300,000 | $96,300 |
Issue of options. $96,300 (Black-Scholes valuation)
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Mark P Diamond | Non-Executive ChairmanNon-Executive Director | Dec 2023 |
Mr Diamond is a pharmaceutical executive with thirty years in the pharmaceutical and biotechnology industries. Mr Diamond served as MD and CEO at ASX listed Antisense Therapeutics. Mr Diamond served in senior product and business development roles at Faulding Pharmaceuticals (now Pfizer).
|
| Mr Hugh Alsop | Non-Executive Director | May 2017 |
Mr Alsop has experience in international business development, partnering, drug development and leadership of scientific teams. Mr Alsop is CEO of Kinoxis Therapeutics. Mr Alsop was CEO of a private company Hatchtech.
|
| Dr Nina Webster | Chief Executive OfficerManaging Director | Aug 2018 |
Dr Webster has experience in the pharmaceutical industry, with roles across strategy, commercialisation, intellectual property, scientific and operational aspects of product development. Dr Webster is the Non-Executive Chairperson for SYNthesis BioVentures.
|
| Dr Sonia Maria Poli | Non-Executive Director | Jul 2015 |
Dr Poli has 25 years' experience in pharmaceutical companies. Dr Poli is an advisor for drug development projects. Dr Poli served as Executive Manager at AC Immune and Chief Scientific Officer at Sybilla Biotech, Minoryx and Addex Therapeutic.
|
| Mr Clinton Snow | Non-Executive Director | May 2023 |
Mr Snow has 20 years in engineering leadership, project delivery, risk management and AI. Mr Snow provides advisory services to a family office with investments in the Australian biotech sector.
|
| Mr Michael (Mike) Tonroe | Chief Financial OfficerCompany Secretary | Jan 2026 |
-
|
| Michael (Mike) Tonroe | Chief Financial OfficerCompany Secretary |
-
|
|
| Dr David Fuller | Chief Medical Officer |
-
|
|
| Dr Robert Shepherd | Chief Operating Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Peter Fletcher Meurs | 91,640,374 | 15.26% |
| Precision Opportunities Fund Ltd <Investment A/C> | 18,000,000 | 3.00% |
| Citicorp Nominees Pty Limited | 15,791,993 | 2.63% |
| Hsbc Custody Nominees (Australia) Limited | 13,865,326 | 2.31% |
| J P Morgan Nominees Australia Pty Limited | 13,144,888 | 2.19% |
| Mr Andrew Coates & Mrs Melinda Coates | 11,337,181 | 1.89% |
| Philip & Julie Scott | 10,300,000 | 1.72% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 8,958,664 | 1.49% |
| BNP Paribas Nominees Pty Ltd <IB Au Noms Retailclient> | 8,183,890 | 1.36% |
| Mr Richard Stanley De Ravin | 6,526,668 | 1.09% |
| Yodambao Pty Ltd <Yodambao Investment A/C> | 4,639,065 | 0.77% |
| Netwealth Investments Limited <Wrap Services A/C> | 4,228,209 | 0.70% |
| BNP Paribas Noms Pty Ltd | 4,088,567 | 0.68% |
| Bavaria Bay Pty Ltd | 3,845,000 | 0.64% |
| Mrs Gwen Murray Pfleger <Pfleger Family A/C> | 3,650,379 | 0.61% |
| Mr David William Pearson & Mrs Susan Dawn Pearson <Pearson Super Fund A/C> | 3,549,224 | 0.59% |
| Blake Nominees Pty Ltd <M And T Super Fund A/C> | 2,773,539 | 0.46% |
| UBS Nominees Pty Ltd | 2,572,670 | 0.43% |
| Alcap Pty Limited <Newbold Family A/C> | 2,000,000 | 0.33% |
| Goldrich Holdings Pty Ltd <Goldrich Investment A/C> | 2,000,000 | 0.33% |
| Mr John Edward Cox & Mrs Evelyn Rita Cox <Jemda Super Fund A/C> | 2,000,000 | 0.33% |
| Ponderosa Investments (WA) Pty Ltd <Ponderosa Investment A/C> | 2,000,000 | 0.33% |
| Mr Roy Sigmund Bergseng & Mrs Vicki Louise Bergseng | 1,800,000 | 0.30% |
